# A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants

> **NCT02280018** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 12 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-49122944, 5 milligram (mg)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02280018
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2015-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02280018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02280018, "A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02280018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*